glad to report that we continue to make advances in all phases of
the cancer program. In our clinic, we are seeing continually more
patients, a gratifying occurrence because patient care is our reason
for existence. And I'm proud to share the results of a recent survey
showing that our clinic staff is handling the increase wonderfully.
Cancer Center patients ranked the staff first in overall clinical
experience out of 20 hospital-based clinics within the UC Davis
Health System. Looking to the future, the regional cancer centers
in Yuba City, Marysville and Merced are well under way, and we are
all eagerly anticipating their opening next year.
clinical trials-clinical research program has greatly benefited
from the guiding hands of clinical trials manager Mike Hughes and
associate director for clinical research Dr. David Gandara. Dr.
Primo Lara, the newest member of the Hematology and Oncology division,
has joined them. Together they have increased our participation
in phase I-phase II trials, an effort that will make more leading-edge
therapies available to our patients. Their work, along with that
of Paul Gumerlock on molecular correlative studies, is the main
reasons why the California Cancer Consortium grant, which includes
our colleagues at the University of Southern California and the
City of Hope, will be headquartered at UC Davis when the grant is
resubmitted next year.
Dr. Carol Richman's guidance, the adult bone marrow transplant program
has just completed its busiest year yet. With the recruitment of
Dr. Doug Taylor from Harvard Medical Center, we will soon be able
to offer this valuable therapy to children as well. Taylor and Richman
have formed the Bone Marrow Transplantation Affinity Group, which
will expand the pediatric and adult portions of our integrated program.
Lam, whom you will meet in this edition, has arrived with his team
from the Arizona Cancer Center at the University of Arizona Medical
Center. He has been a great addition to our program, bringing new
vision and excitement to the clinical research and translation portions
of the cancer effort at UC Davis.
Kung continues to build a signal transduction program. He has recruited
two outstanding researchers, Hongwu Chen of the Salk Institute and
Kermit Carraway from Harvard, and we eagerly await their arrival
this winter. In a future Synthesis we will introduce you to these
doctors and their important work.
all that accomplished, we are now concentrating on completing recruitment
in three remaining leadership areas: breast cancer, biostatistics
and cancer control. When we finish these recruitments we expect
to have the necessary components for our Cancer Center Support Grant,
and to officially apply for designation as a comprehensive cancer
center from the National Cancer Institute.
I want to thank our volunteers and those of the Active 20-30 Club
of Greater Sacramento #1032 for making it possible to hold our first-ever
fund-raising gala, Passport to Morocco, on Nov. 6. We in the cancer
program are extremely grateful for their dedicated efforts in making
this event a reality.
Ralph W. deVere White, MD
Table of Contents |
To our Readers |
Building on Basics
Focusing on Patients |
In Translation |
Campus Connection |
News in Brief
UC Davis Health System |
© 2000, 2001, 2002 UC Regents. All rights reserved.
UC Davis Cancer Center